GlobeNewswire by notified

FDA requests supplementary information for Acarix breakthrough designation request for heart failure diagnosis

Share

Press release(MAR)
Malmö, Sweden, April 1, 2022  

FDA requests supplementary information for Acarix breakthrough designation request for heart failure diagnosis

The Food and Drug Administration (FDA) has requested supplementary information in reviewing the breakthrough designation request from Acarix for its innovative AI-based technology for heart failure diagnosis in USA.

 “We appreciate the diligence and feedback by FDA regarding the review of our application for breakthrough designation for our AI-based diagnostic technology for heart failure. The team is now prioritizing the work based on the concrete proposals for supplementation we have received so that we can respond to the FDA as soon as possible. Our goal is to expand our AI-based technology to also include heart failure, where rapid access to diagnostic information also can guide optimal patient care and yield improved clinical outcomes faster” says Helen Ljungdahl Round, CEO.

The new Acarix Seismo System is an AI-powered, non-invasive method that offers a simple, rapid risk assessment for patients with suspected heart failure in less than 10 minutes. Acarix breakthrough application is based on clinical data generated from the Seismo study performed in Denmark.

Heart failure affects more than 6 million people in the USA at costs exceeding $30 billion per year. It is a progressive condition that worsens over time, if left untreated. Treatment options depend on the stage of heart failure, from lifestyle changes and medications in the early stages to implantation of cardiac devices and medications in later stages. The availability of a rapid and cost-effective diagnostic tool to help quickly guide early intervention has significant potential to improve clinical outcomes of heart failure. Acarix intends to strengthen its leading position using AI based technology in cardiac care and patient management.  


For more information contact:
Helen Ljungdahl Round, CEO, phone +1 267 809 1225, email helen.round@acarix.com

This information is information that Acarix AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation 596/2014. The information was submitted for publication, through the agency of the contact persons set out above, at the time stated by Acarix news distributor GlobeNewswire at the publication of this press release.

About Acarix:
Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor®System calculates a patient-specific CAD-score non-invasively in less than 10 minutes and can help rule out more than one third of patients with at least 96% certainty (in a population with approx. 10% CAD prevalence). Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, certifiedadviser@redeye.se) is Certified Advisor of Acarix. For more information, please visit www.acarix.com.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Prosafe SE: Annual reporting for 202319.3.2024 12:18:40 CET | Press release

Today, Prosafe publishes its Annual report, Transparency Act Statement and Remuneration report for 2023. The Annual report for 2023 includes the annual accounts, the sustainability report and the corporate governance report. The reports are attached and also available on https://www.prosafe.com/investor-information/annual-reports/ and on https://newsweb.oslobors.no/ Prosafe has also published its annual financial statements in European Single Electronic Format (ESEF), available as an attachment to this release. Prosafe is a leading owner and operator of semi-submersible accommodation vessels. The company is listed on the Oslo Stock Exchange with ticker code PRS. For more information, please refer to www.prosafe.com Stavanger, 28 March 2023 Prosafe SE For further information, please contact: Terje Askvig, CEO Phone: +47 952 03 886 Reese McNeel, CFO Phone: +47 415 08 186 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading A

Danske Bank A/S, ledende medarbejderes transaktioner19.3.2024 12:08:46 CET | pressemeddelelse

19. marts 2024 Indberetning nr. 24/2024 Ændring i aktiebesiddelser hos Danske Banks indberetningspligtige i henhold til EU-forordningen om markedsmisbrug I forbindelse med Danske Bank A/S’ aktietilbagekøbsprogram sælger APMH Invest A/S løbende aktier i Danske Bank A/S pro rata. For yderligere detaljer henvises til de vedhæftede skemaer, hvori transaktioner udført af personer med ledelsesansvar og personer med nær tilknytning til disse skal indberettes og offentliggøres. Kontakt: Stefan Singh Kailay, Head of Media Relations, tel. +45 45 14 14 00 Vedhæftet fil APMH Invest A_S - salg - 2024-03-18

Danske Bank A/S, transactions by persons discharging managerial responsibilities19.3.2024 12:08:46 CET | Press release

19 March 2024 Notification no. 24/2024 Transactions made by persons obliged to report transactions to the Danish FSA and Nasdaq Copenhagen, cf. the EU Market Abuse Regulation. In connection with the share buy-back program in Danske Bank A/S, APMH Invest A/S continuously sells shares pro rata. For further details, please find the attached templates for notifications and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them. Contact: Stefan Singh Kailay, Head of Media Relations, tel. +45 45 14 14 00 Attachment APMH Invest AS - sale - 2024-03-18

SPEVIGO® approved for expanded indications in China and the US19.3.2024 12:00:00 CET | Press release

Generalized pustular psoriasis (GPP) is a rare, chronic, heterogenous neutrophilic inflammatory disease associated with skin and systemic symptoms, such as fever, pain, and fatigue1,2,3,4In China, SPEVIGO®’s expanded approval adds the reduction of occurrences of GPP in pediatric patients aged 12 and above weighing ≥40 kg, and adults5The US FDA’s approval expands the use of SPEVIGO® to include the treatment of GPP in adults and pediatric patients aged 12 and above weighing ≥40 kg, making it the first targeted therapy that addresses the need for acute and chronic treatment for GPP patients6SPEVIGO® is currently approved in 48 countries7 Boehringer Ingelheim today announced that the US Food and Drug Administration (FDA) has approved SPEVIGO® (spesolimab-sbzo) injection for the treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients aged 12 and above weighing ≥40 kg.5 This approval follows the Chinese National Medical Products Administration’s (NMPA) recent appro

Equinor ASA: Kjøp av aksjer til aksjeprogram for ansatte19.3.2024 11:57:54 CET | Pressemelding

Nedenfor følger informasjon om transaksjoner knyttet til tilbakekjøpsprogrammet for Equinor ASA (OSE:EQNR, NYSE:EQNR) til bruk i aksjebaserte insentivprogrammer for ansatte og ledelse. Dato for annonsering av tilbakekjøpsprogrammet: 7. februar 2024. Varighet av tilbakekjøpsprogrammet: 15. februar 2024 til 15. januar 2025. Størrelse av tilbakekjøpsprogrammet: Samlet kjøpesum i tilbakekjøpsprogrammet er inntil NOK 1.156.000.000 og det maksimale antall aksjer som kan erverves er 16.800.000, hvorav opp til 7.400.000 aksjer kan erverves i perioden fra 15. februar 2024 til 15. mai 2024, og opptil 9.400.000 aksjer kan erverves i perioden fra 16. juni 2024 til 15. januar 2025. Den 15. mars 2024 kjøpte Equinor ASA totalt 482.159 egne aksjer ved Oslo Børs til en gjennomsnittspris på NOK 279,9906 pr. aksje. Oversikt over transaksjoner: DateAggregert volum (antall aksjer)Vektet gjennomsnittspris pr. aksje (NOK) Total transaksjonsverdi (NOK) 15 mars 2024482.159279,9906134.999.988Totalt tidligere of

HiddenA line styled icon from Orion Icon Library.Eye